

Medication Assisted Treatment Crosswalk

A joint initiative of the University of New Hampshire, Institute for Health Policy & Practice, Citizens Health Initiative and the JSI/Community Health Institute, NH Center for Excellence.

Purpose: To identify similarities and differences in medication assisted treatment (MAT) best practice recommendations through cross reference of the NH Medication Assisted Treatment Guidance Document and the Substance Abuse and Mental Health Services Administration (SAMHSA) Treatment Improvement Protocol (TIP) 63.

Results: Both documents align in their fundamental approach to MAT despite differences in scope and audience. TIP 63 provides background information on all three FDA-approved MAT medications, and it addresses practitioners and support staff, those with opioid use disorder (OUD), and family members and friends of those with OUD. Its purpose remains broadly educational while the NH MAT Guidance Document addresses practitioners and support staff in the development and implementation of MAT best practices.



Treatment Improvement Protocol (TIP) 63: Medications for Opioid Use Disorder

Scope: Comprehensive review of medications used to treat opioid use disorder — methadone, naloxone, and buprenorphine to include strategy recommendations.

Audience:

- ✓ Medical Professionals
- ✓ Individuals and Families Experiencing Opioid Use Disorder



Guidance Document on Best Practices: Key Components for Delivering Community-Based Medication Assisted Treatment Services for Opioid Use Disorders in NH

Scope: Comprehensive review of best practice recommendations and resources for developing and implementing medication assisted treatment.

Audience:

- ✓ Practitioners and Support Staff Seeking to Implement MAT

REVIEW OF MEDICATIONS

TOPIC AREA	TIP 63	MATG UIDANCE DO CUMENT
Re vie w of Me dic a tio ns	●	●
Me tha do ne	●	●
Bup re no rp hine	●	●
Fo m ula tio ns	●	●
Na ltre xo ne	●	●
Fo m ula tio ns	●	●
Do sing Co nsid e ra tio ns	●	●
Drug Inte ra c tio ns	●	●
Co ntra ind ic a tio ns	●	●
Sid e Effe c ts	●	●

CLINICAL CONSIDERATIONS

TOPIC AREA	TIP 63	MAT GUIDANCE DOCUMENT
Clinical Considerations	•	•
Screening	•	•
Alcohol	•	•
Tobacco	•	•
Drug	•	•
Evaluation/Assessment	•	•
ASAM Criteria	•	•
Treatment History	•	•
Social History	•	•
Family History	•	•
Diagnosis	•	•
Physical Exam	•	•
Laboratory Testing	•	•
Opioid Withdrawal Scales	•	•
Opioid Overdose	•	•
Informed Consent	•	•
Patient Selection	•	•
Medically Supervised Withdrawal	•	•
Induction	•	•
Duration of Treatment	•	•
Dose Tapering & Discontinuation	•	•
Medical Management Strategies	•	•
Treatment Planning	•	•

ADMINISTRATIVE CONSIDERATIONS

TOPIC AREA	TIP 63	MAT GUIDANCE DOCUMENT
Administrative Considerations	●	●
Treatment Settings	●	●
Outpatient	●	●
Residential	●	●
Hospital	●	●
Staffing	●	●
Establishing a Core Team	●	●
Recruiting and Retaining Staff/Training	●	●
Care Coordination	●	●
Communication	●	●
Confidentiality	●	●
Diversions Control Policies	●	●
Buprenorphine	●	●
Using a Recovery-Oriented Approach to Treatment	●	●
Person-Centered Care	●	●
Trauma-Informed Care	●	●
Bias, Discrimination and Stigma	●	●
Billing & Reimbursement	●	●
Non-Insurance Payment Model	●	●
Third-Party Payer Reimbursement Model	●	●
Insurance Strategies	●	●
Drug Testing	●	●
Testing for Medication Adherence	●	●
Testing for Complicating Substances	●	●
Referral to Counseling and Other Psychosocial Supports	●	●
SUD Treatment	●	●
Psychosocial Interventions	●	●
Recovery Support Services	●	●
Mutual Help Groups	●	●
Family and Social Supports	●	●
Storage of Medications	●	●
Record Keeping	●	●
DEA Inspections	●	●
Patient Education	●	●
Advocacy	●	●

RESOURCES

TOPIC AREA	TIP 63	MAT GUIDANCE DOCUMENT
Resources	●	●
MAT Quality Planning Tool		●
Sample Treatment Agreement	●	●
Sample Consent Form	●	●
Urine Drug Testing Window of Detection	●	
Flow Chart of Best Practices		●
Sample Treatment Timeline		●
Sample Screening Assessment	●	
Provider Informational, Educational and Decision-Making	●	
Sample Goal Setting Form	●	
Sample Medical Management Visit Form	●	
Sample Patient Urine Drug Screen and Medication Count	●	
Sample Pharmacy Tablet/Film Count Form	●	
Sample Buprenorphine Diversion Control Policy	●	

Suggested Citations

Treatment Improvement Protocol (TIP) 63: Medications for Opioid Use Disorder

Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63, Full Document. HHS Publication No. (SMA) 18-5063FULDOC. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2018.

Guidance Document on Best Practices: Key Components for Delivering Community-Based Medication Assisted Treatment Services for Opioid Use Disorders in NH

New Hampshire Department of Health and Human Services, Bureau of Drug and Alcohol Services. Guidance Document on Best Practices: Key Components for Delivering Community-Based Medication Assisted Treatment for Opioid Use Disorders in New Hampshire. Second Edition, April 2018.